Core Viewpoint - The inclusion of the innovative long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing), in the 2025 National Medical Insurance Drug List marks a significant step towards making diabetes treatment more accessible in China, aligning with the "Healthy China 2030" initiative [1] Group 1: Company Developments - Silver诺医药-B (02591) saw its stock price increase by 3.43%, reaching HKD 32, with a trading volume of HKD 20.74 million [1] - The company’s drug, Icosapent Ethyl, is now officially recognized for the treatment of blood sugar control in adult patients with type 2 diabetes, effective from January 1, 2026 [1] Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the National Medical Insurance Drug List is a crucial advancement for the accessibility of innovative diabetes treatments in China [1] - The "National Guidelines for Diabetes Prevention and Management (2025)" lists Icosapent Ethyl as a key injectable GLP-1RA, providing policy and regulatory support for its use in primary healthcare settings [1] - The guidelines emphasize the importance of GLP-1RA for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those needing weight management [1]
港股异动 | 银诺医药-B(02591)盘中涨超3% 依苏帕格鲁肽ɑ获国家基层糖尿病防治指南推荐